CD38 and autoimmune hemolytic anemia: However, additional support for the role of CD38-targeted therapy in autoimmune diseases comes from 2 case reports that recently showed the potency of daratumumab in the treatment of post-transplant autoimmune hemolytic anemia refractory to established options, and treatment-refractory pure red blood cell aplasia after ABO-mismatched allogeneic stem cell transplantation [10,11].